Reimagining Medicine slide image

Reimagining Medicine

Company overview Financial review Innovation: Pipeline overview 2022 events¹ NME Lead Regulatory H1 Pluvicto™ mCRPC (US/EU ✓) decisions H1 VijoiceⓇ PROS (US) H2 Scemblix 3L CML (JP/EU✓) H2 tislelizumab ESCC 2L (US) 10 H1/H2 JakaviⓇ acute & chronic GVHD (EU /JPx13) H1/H2 KymriahⓇ r/r follicular lymphoma (US/EU ✓ /JP✓ ) H1/H2 BeovuⓇ DME (US/EU/JP ✓) ensovibep COVID-19 (US) H1/H2 Cosentyx® HS (EU/US ✓) H1/H2 tislelizumab NSCLC (EU/US x²) Submissions H1 H2 tislelizumab 1L Nasopharyngeal cancer (US x2) H2 Cosentyx Psoriatic Arthritis IV (US) 12 Submissions- H2 enabling readouts H2 canakinumab NSCLC Ph3 CANOPY-A (PE not met) iptacopan PNH Ph3 APPLY-PNH✓ H2 Pluvicto™ pre-taxane mCRPC Ph3 PSMAfore³✓ 2023 priorities Appendix Abbreviations Innovation: Clinical trials ✓ Achieved to plan X Not achieved to plan Other readouts H1 sabatolimab HR-MDS Ph2 √4 H1 CosentyxⓇ Lichen planus Ph2 PRELUDE5✓ (PE not met) H1 CosentyxⓇ axSpA IV Ph3 INVIGORATE-1 ✓ H1 icenticaftor COPD Ph2b √6 H2 UNR844 presbyopia Ph2 READER (PE not met) Ph3/pivotal study starts H1 CosentyxⓇ peripheral SpA x7 H1 OAV101 SMA IT STEER ✓ H1 ensovibep COVID-19 (EMPATHY Part B) x8 H2 JDQ443 NSCLC mono H2 ianalumab Sjögren's Syndrome ✓ H2 ianalumab Lupus Nephritis ✓ H2 ociperlimab solid tumors x H2 PluvictoⓇ nmCRPC x11 H2 YTB323 2L DLBCL9x H2 OAV101 SMA IT Ph3b STRENGTH ✔ PE: Primary Endpoint Note: KisqaliⓇ NATALEE Ph3 readout removed (2023 event as shared at Q1 2023). 1. Selected. 2. No US submission planned. 3. Could move to early 2023. 4. Submission will be based on Ph3 results. 5. Primary endpoint at Wk16 not met. 6. Ph2b DRF demonstrated dose response across multiple endpoints, study results presentation end 2022. Out-licensing planned. 7. Strategy update. 8. No definite start date for the IV Ph3 clinical trial can be provided at this time. 9. Development strategy updated. 10. FDA deferred action pending completion of required inspections. 11. Ph3 in nmCRPC shifting to Ph2, with FPFV in 2023. 12. Submission included also ankylosing spondylitis IV and non-radiographic axial SpA IV. 13. Base case approval moved to H1 2023. 50 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation